Zobrazeno 1 - 10
of 156
pro vyhledávání: '"A. V. Menshikov"'
Autor:
Alexander V. Sultanbaev, Shamil I. Musin, Konstantin V. Menshikov, Nadezda I. Sultanbaeva, Irina A. Tuzankina, Danila O. Lipatov, Irina A. Menshikova, Mikhail V. Sultanbaev, Dmitry A. Kudlay, Andrey P. Prodeus
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 132-138 (2024)
Background. In oncology, of particular interest is the study of the T-cell receptor excision circles (TREC) and the κ-deletion B-cell receptor excision circles (KREC), which are extrachromosomal DNA structures. In many malignancies, the effectivenes
Externí odkaz:
https://doaj.org/article/5ed0020daa5b4dd1849ab3aab2568c61
Publikováno v:
RUDN journal of Sociology, Vol 24, Iss 2, Pp 354-378 (2024)
The article considers the main participants of artificial sociality (people and artificial intelligence tools) and communication between them. The study is predominantly sociological but includes an attempt to address the mathematical-technological a
Externí odkaz:
https://doaj.org/article/91d3be2cd7884de997117de3c997d68c
Autor:
Igor V. Samoylenko, Yulia M. Kolontareva, Ekaterina V. Kogay, Natalia V. Zhukova, Igor A. Utyashev, Mikhail E. Ivannikov, Konstantin V. Menshikov, Maxim V. Zinkevich, Kristina V. Orlova, Yulia V. Vakhabova, Mikhail V. Volkonsky, Natalia A. Beliaeva, Ivan I. Butkov, Elena V. Karabina, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Vitaliy D. Sychev, Oxana S. Cheplukhova, Vera V. Chernova, Alexandr N. Yurchenkov, Ksenia G. Babina, Nikita A. Savelov, Lev V. Demidov
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundAmong several treatment options for BRAF-mutant metastatic melanoma, a combination of BRAF inhibitor, MEK inhibitor, and anti-PDL1 antibody seems to be a new emergent approach recently registered in the Russian Federation. It is still not c
Externí odkaz:
https://doaj.org/article/91fe8f49496a4d33a30456c3a9114984
Autor:
Sh. I. Musin, K. V. Menshikov, A. V. Sultanbayev, I. A. Sharifgaleev, V. V. Ilyin, A. O. Guz, A. N. Rudyk, S. V. Osokin, N. A. Sharafutdinova, A. V. Chashchin, A. V. Garev, T. R. Baymuratov
Publikováno v:
Опухоли головы и шеи, Vol 13, Iss 4, Pp 10-18 (2024)
Introduction. Surgical intervention remains the main method for treatment of the oral mucosa cancer. The generally accepted standard of the resection boundary that provides optimal local control is 5 mm. Adequate boundaries of indentation and choice
Externí odkaz:
https://doaj.org/article/4d2629e770b2422faaeba2d21c608469
Autor:
Maria I. Volkova, Alexey S. Kalpinskiy, Olesya A. Goncharova, Konstantin V. Menshikov, Elena V. Karabina, Aleksand S. Dergunov, Natalya I. Polshina, Elena N. Alexandrova, Andrey A. Lebedinets, Alexey К. Panov, Alexander V. Sultanbaev, Evgeny A. Usynin, Mikhail V. Volkonskiy, Viktorya V. Mikhalyuk, Ruslan A. Zukov, Yulia V. Anzhiganova, Magomed A. Gusniev, Elena N. Igumnova, Svetlana V. Kuzmicheva, Ilya A. Pokataev, Anna S. Olshanskaya, Natalia I. Pervakova, Elvira L. Parsadanova, Tatyana A. Sannikova, Alexandr A. Bystrov, Daria M. Dubovichenko, Mukhitova R. Miliausha, Viacheslav A. Chubenko, Konstantin A. Shkret, Mariya N. Gorshenina, Mavzhuda К. Davlatova, Alina E. Kosareva, Olga A. Lutoshkina, Oxana A. Maslova, Maria V. Makhnutina, Anna V. Mishina, Makhabbat Zh. Murzalina, Oksana A. Podyacheva, Sergey A. Kalinin, Ovsep A. Mailyan, Alfiya R. Safarova, Ksenia O. Semenova, Mariya A. Strokova, Ekaterina Yu. Urashkina, Olesya S. Shmygina
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 39-47 (2024)
Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients with advanced renal cell carcinoma (RCC). Materials and methods. The Russian phase IV observational study included 151 patients with advanced RCC who r
Externí odkaz:
https://doaj.org/article/b8f04fb084054d4fa93d3b87907a155b
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Konstantin V. Menshikov, Shamil I. Musin, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva, Radmir R. Rakhimov, Danila O. Lipatov, Irina A. Menshikova, Adel A. Izmailov, Elena E. Lipatova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 65-72 (2024)
Background. The combination of alpelisib with fulvestrant is the optimal targeted endocrine therapy for patients with hormone-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with mutations in the PIK3CA gene. This regimen has been
Externí odkaz:
https://doaj.org/article/e3c845b4890840dc9606d4f6fb39fad8
Autor:
Alexander V. Sultanbaev, Irina V. Kolyadina, Irina R. Gilyazova, Ainur F. Nasretdinov, Shamil I. Musin, Nadezda I. Sultanbaeva, Konstantin V. Menshikov
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 48-55 (2024)
Carriers of germinal mutations are at high risk of developing malignant neoplasms, characterized by an early age of manifestation, an aggressive course, and a high risk of recurrence. The wide introduction of medical genetic testing in the target pop
Externí odkaz:
https://doaj.org/article/e66b61080f3f4d0e823f5fd21c6b01f5
Publikováno v:
RUDN journal of Sociology, Vol 23, Iss 4, Pp 825-838 (2023)
The article aims at identifying the medium-term fertility trend in Latvia. The main research question is whether it is possible in the near future to increase fertility in Latvia, as planned in the “Strategy for the Reproduction of the Nation FAMIL
Externí odkaz:
https://doaj.org/article/b9a2c31a231b4a9184e72f0aa7f714cb
Publikováno v:
Baltic Region, Vol 15, Iss 3, Pp 45-65 (2023)
The article explores the growing role of artificial intelligence (AI) in entrepreneurship education within universities. This exploration is set against the backdrop of the rapid and widespread integration of AI technologies across economic and other
Externí odkaz:
https://doaj.org/article/53db5f288cc0409882e07fea7d8bbaa6
Autor:
A. A. Izmailov, R. R. Rakhimov, A. V. Sultanbayev, K. V. Menshikov, I. R. Gilyazova, V. M. Zabelin
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 4, Pp 109-117 (2023)
Over the past 5 years, checkpoint inhibitors including anti-CTLA-4 and anti-PD-1/PD-L1 blockers have changed approaches to therapy of metastatic renal cell cancer. However, more than 55 % of patients with advanced kidney cancer remain resistant to im
Externí odkaz:
https://doaj.org/article/c09d80d42bcb44f89c9ea3942409b438